Patent SG-11201807051V-A (SG)
Title: Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
Inventor: DENG LIANG
IPC: A61P35/00
Filed: 2017-02-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 31 August 2017 (31.08.2017) WIPO I PCT (10) International Publication Number WO 2017/147553 A2 111111111111110111011111111111010111110 0101111111111111111011011111111111110111111 (51) International Patent Classification: A61K 48/00 (2006.01) C12N 15/86 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/300,066 25 February 2016 (25.02.2016) US (72) Inventors: DENG, Liang; C/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). SHUMAN, Stewart; C/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). WOLCHOK, Jedd; C/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). MERGHOUB, Taha; C/o Memorial Sloan-Ketter- ing Cancer Center, 1275 York Avenue, New York, NY 10021 (US). WANG, Weiyi; C/o Memorial Sloan-Ketter- ing Cancer Center, 1275 York Avenue, New York, NY 10021 (US). DAI, Peihong; C/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). YANG, Ning; C/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). (74) Agents: GOGORIS, Adda C. et al.; Leason Ellis LLP, One Barker Avenue, Fifth Floor, White Plains, NY 10601 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). ished: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a)) PCT/US2017/019548 (81) 25 February 2017 (25.02.2017) English English (71) Applicant: MEMORIAL SLOAN-KETTERING CAN- CER CENTER [US/US]; 1275 York Avenue, New York, NY 10021 (US). (84) Publ W O 20 17 / 14755 3 A2 (54) Title: REPLICATION COMPETENT ATTENUATED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT THE EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY (57) : The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK) with and without the expression of human F1t3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses - can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.